CLINICAL, METABOLIC AND INFLAMMATORY FEATURES OF CHRONIC HEART FAILURE IN PATIENTS WITH METABOLIC SYNDROME AND RESULTS OF COMPLEX THERAPY
Keywords:
Chronic heart failure, metabolic syndrome, insulin resistance, IL-6, C-reactive protein, NT-proBNP, HOMA-IR, exoccardiography, complex therapy.Abstract
Relevance. Metabolic syndrome (MS) is one of the most important risk factors for the development and severity of chronic heart failure (SIU). Insulin resistance, chronic low inflammation, dyslipidemia and obesity can lead to structural and functional restructuring of the myocardium, exacerbating the clinical course of the disease. Current research emphasizes that biomarkers such as IL-6, C-reactive protein (CRP), and NT-proBNP have important diagnostic and prognostic value in assessing disease severity and prognosis.
Purpose. Study of clinical , metabolic, and inflammatory features of chronic heart failure and evaluation of clinical, laboratory, and instrumental efficacy of complex therapy in patients with metabolic syndrome. Material and methods. The study involved 200 patients diagnosed with chronic heart failure with metabolic syndrome between the ages of 40 and 75. Patients were divided into the standard therapy group (n = 100) and the complex therapy group (n = 100). All patients underwent clinical examination, anthropometric evaluation, exocardiography, NT-proBNP, IL-6, CRP, HbA1c, insulin, HOMA-IR, lipid spectrum, and a 6-minute walk-in test. Results. In patients treated with complex therapy, NYHA functional class improved, 6-minute walking distance increased, and NT-proBNP, IL-6, CRP, and HOMA-IR scores decreased significantly (p<0.05). Exocardiographic examinations showed increased left ventricular ejection fraction, decreased diastolic dysfunction rate, and slowed cardiac remodeling.
References
1.McDonagh T.A., Metra M., Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368.
2.Heidenreich P.A., Bozkurt B., Aguilar D. et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145:e895–e1032. doi:10.1161/CIR.0000000000001063.
3.McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine. 2019;381:1995–2008. doi:10.1056/NEJMoa1911303.
4.Packer M., Anker S.D., Butler J. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine. 2020;383:1413–1424. doi:10.1056/NEJMoa2022190.
5.Solomon S.D., McMurray J.J.V., Anand I.S. et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine. 2022;387:1089–1098. doi:10.1056/NEJMoa2206286.
6.Bozkurt B., Coats A.J.S., Tsutsui H. et al. Universal Definition and Classification of Heart Failure. Journal of Cardiac Failure. 2021;27(4):387–413.
7.Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of heart failure. European Heart Journal. 2016;37:2129–2200.
8.Paulus W.J., Tschope C. A novel paradigm for heart failure with preserved ejection fraction. Journal of the American College of Cardiology. 2013;62(4):263–271.
9.Murphy S.P., Ibrahim N.E., Januzzi J.L. Heart Failure with Reduced Ejection Fraction. JAMA. 2020;324(5):488–504.
10.Savarese G., Becher P.M., Lund L.H. Global burden of heart failure. Cardiac Failure Review. 2023;9:e16.
11.Anker S.D., Butler J., Filippatos G. et al. Empagliflozin in patients hospitalized for acute heart failure. Nature Medicine. 2021;27:1635–1643.
12.Cosentino F., Grant P.J., Aboyans V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes and cardiovascular diseases. European Heart Journal. 2020;41:255–323.
13.Alberti K.G.M.M., Eckel R.H., Grundy S.M. et al. Harmonizing the Metabolic Syndrome. Circulation. 2009;120:1640–1645.
